Direkt zum Inhalt
Merck

Fortfahren mit

L1295

Lamivudin

≥98% (HPLC), nRTI inhibitor, powder

Synonym(e):

2′,3′-Dideoxy-3′-thiacytidin

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
Ihnen/SKUVerfügbarkeitPreis
10 mg
Warenkorb auf Verfügbarkeit prüfen
€ 95,00
50 mg
Warenkorb auf Verfügbarkeit prüfen
€ 379,00

Über diesen Artikel

Empirische Formel (Hill-System):
C8H11N3O3S
CAS-Nummer:
Molekulargewicht:
229.26
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

€ 95,00


Warenkorb auf Verfügbarkeit prüfen

Sonderanfertigung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


Produktname

Lamivudin, ≥98% (HPLC), powder

Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

water: 10 mg/mL, clear

originator

GlaxoSmithKline

storage temp.

room temp

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

Application

Lamivudine has been used to deplete the Hepatitis B Virus (HBV) covalently closed circular DNA (cccDNA) forms for the preparation of inverse nested PCR.

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
PHR13651356836Y0000425
Lamivudin United States Pharmacopeia (USP) Reference Standard

USP

1356836

Lamivudin

Lamivudin European Pharmacopoeia (EP) Reference Standard

Y0000425

Lamivudin

description

≥98% (HPLC), powder

description

Pharmaceutical Secondary Standard; Certified Reference Material

description

United States Pharmacopeia (USP) Reference Standard

description

European Pharmacopoeia (EP) Reference Standard

assay

≥98% (HPLC)

assay

-

assay

-

assay

-

form

powder

form

-

form

-

form

-

Quality Level

100

Quality Level

300

Quality Level

-

Quality Level

-

storage temp.

room temp

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

solubility

water: 10 mg/mL, clear

solubility

-

solubility

-

solubility

-

color

white to beige

color

-

color

-

color

-


Still not finding the right product?

Explore all of our products under Lamivudin


pictograms

Health hazard

signalword

Warning

Lagerklasse

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

target_organs

Blood

Hazard Classifications

Aquatic Chronic 3 - Repr. 2 - STOT RE 2



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Questions

Reviews

No rating value

Active Filters